Skip to Content

Viviant Approval Status

FDA Approved: No
Brand name: Viviant
Generic name: bazedoxifene
Company: Pfizer Inc.
Treatment for: Prevention of Osteoporosis

Viviant (bazedoxifene) is a selective estrogen receptor modulator (SERM) in development for the prevention of postmenopausal osteoporosis.

Development Status and FDA Approval Process for Viviant

DateArticle
May 27, 2008Wyeth Receives Approvable Letter From FDA for Bazedoxifene for the Treatment of Postmenopausal Osteoporosis
Dec 26, 2007Wyeth Receives Approvable Letter from FDA for Bazedoxifene for the Prevention of Postmenopausal Osteoporosis - Dec 26, 2007
Dec 17, 2007Wyeth Provides Update on Regulatory Review of Viviant (bazedoxifene)
Apr 24, 2007Wyeth Receives Approvable Letter from FDA for Bazedoxifene for the Prevention of Postmenopausal Osteoporosis - May 1, 2007
Jun 26, 2006Wyeth Submits Two NDAs for Women’s Health Therapies

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide